1. Record Nr. UNINA9910255193503321

Autore Jiang Li

Titolo Regulating Human Embryonic Stem Cell in China : A Comparative Study

on Human Embryonic Stem Cell's Patentability and Morality in US and

EU / / by Li Jiang

Pubbl/distr/stampa Singapore:,: Springer Singapore:,: Imprint: Springer,, 2016

ISBN 981-10-2101-5

Edizione [1st ed. 2016.]

Descrizione fisica 1 online resource (XVIII, 200 p. 1 illus.)

Disciplina 344.0321

Soggetti Medical laws and legislation

Mass media

Law Bioethics Medical Law

IT Law, Media Law, Intellectual Property

Lingua di pubblicazione Inglese

Formato Materiale a stampa

Livello bibliografico Monografia

Nota di bibliografia Includes bibliographical references.

Nota di contenuto Values of Human Embryonic Stem Cell Research, the phenomenon of

"Stem Cell Tourism" and Inadequate regulation of Human Embryonic Stem Cell in China -- The Moral Maze In Human Embryonic Stem Cell Research: the moral status of human embryo and the moral source of human embryonic stem cell -- China: inconsistent moral standards of human embryonic stem cell research between patent law and practical application -- The United States: Inconsistent policies on federal funding control of human embryonic stem cell research -- The European Union: Inconsistent interpretations of moral provisions in Patent Convention addressing human embryonic stem cell research -- A proposal for controlling human embryonic stem cell research in China: regulate research itself in a reconciled human embryonic stem

cell regulation at the international regime. .

Sommario/riassunto The general scope of the book is the patentability and morality of

human embryonic stem cell research in US, EU and China. The book observes fraudsters operate unsafe human embryonic stem cell therapies and officialdom turns a blind eye to the immoral human embryonic stem cell research in China. The book highlights that both patent control and federal control are inefficient and ineffective way to monitoring human embryonic stem cell research. The book finally proposed an approach for china to regulating human embryonic stem cell research-regulating research itself at the reconciled international regime. The potential reader includes academics and practitioners dealing with intellectual property, patent law and stem cell inventions. The topic discussed will also be interesting to a broad readership, including experts, regulators, policy makers and medical researchers in both ethical and legal disciplines in the field of embryonic stem cell research.